EBS Technologies CEO Ulf Pommerening said it is well-known that there is a tremendous unmet clinical need for the treatment of vision impairment caused by a variety of different neurological disorders, such as neuropathy of the optic nerve.

"Three out of five persons who are disabled from impaired vision as a result of optic nerve neuropathy, brain injury, or stroke are potentially treatable with our NEXT WAVE™ therapy, which is why we are very excited about the University Medical Center Hamburg-Eppendorf’s pioneering role in applying NEXT WAVE™ therapy to patients," Pommerening added.

In June 2013, EBS announced the results of a multi-center, 82-patient clinical trial of its NEXT WAVE brain stimulation device. About one-half of the clinical trial patients were given a 40-minute treatment protocol for 10 consecutive days with the NEXT WAVE device.

With an average increase of 24% of the total visual field, NEXT WAVE-treated patients showed significantly better improvements in stimulation of their total visual field compared with patients in the control group who did not receive NEXT WAVE stimulation. All patients had vision impairment lasting at least six months prior to the clinical trial and had exhausted all standard therapeutic options to improve their vision.

The NEXT WAVE technology enables a unique and patient-centric revitalization of selective communication paths between neurological cells, which may have been impaired due to brain injury caused by for example trauma, degeneration or tumor resection.

The non-invasive therapy utilizing the patented NEXT WAVE technology is clinically validated to restore vision impairment by 20-30% after optical pathologies (such as glaucoma) and brain dysfunction.